Net income to common was $6.1 million, or $0.14 per share. Participation rents rose about $11.4 million, and direct farming operations generated a net profit of about $2.9 million. The advisor waived its third quarter incentive fee.
The net loss was $27.3 million, or $0.58 per share, against about $0.52 expected. R&D expense rose to $24.6 million from $14.6 million, and G&A rose to $5.1 million from $2.5 million. Cash and marketable securities were $430.2 million versus $457.5 million at June …
Revenue rose 49% to $461.5 million, about 5% ahead of plan and above the roughly $444 million analysts expected. Engineering and maintenance grew 39%, and infrastructure deployment grew 63%. Adjusted EBITDA was $64.5 million, a 14% margin, up 120 basis points despite fuel and …
Fiscal second quarter revenue grew 19.8% to $50.3 million from $42 million a year ago, driven by higher shipments to its major U.S. customer and others.Gross Profitincreased 45.4% to $9.1 million, and gross margin rose 320 basis points to 18.2% on higher U.S. shipments, …
Product sales made up about 88% of revenue and grew roughly 300%, with shipments to 22 product customers versus 18 a year ago. Management said it is focusing on fewer programs and strategic customers, and the new Texas Forge 2Facilityis central to that plan.
Revenue was up 43% from the second quarter, driven by $5.4 million of Fabric AI development revenue and $3.1 million of color microLED grant revenue. Product revenue was $8.8 million. The operating loss narrowed to $0.5 million, and operations generated about $2.4 million in …
Gross margin was 41.4%, and adjusted EBITDA was $1.3 million, the fifth straight positive quarter. The net loss narrowed to $1.7 million, or $0.02 per share, from $2.9 million a year ago. New product development spending doubled to $2 million, and operating expenses of …
Volume production is now expected to start in 2028, not the second half of 2027, as silicon photonics foundries run slower production cycles and process design kit qualification takes longer. Management says the delay reflects foundry timelines rather than weaker customer demand, and that …
Net product sales of Yutrepia grew 31% from the second quarter to $222.7 million, an increase of about $52 million. Paid patientDemandsupplied $212.2 million of that total. It was the fifth consecutive quarter of growth in prescriptions,Revenueand adjusted EBITDA, which reached $140.5 million.
Cauchari-Olaroz ran at about 95% of design capacity with cash costs of about $5,800 per ton and a 67% cash operating margin. Year-to-date production was 28,490 tons. Revenue rose 6% from the second quarter to $184 million on 18% higher volumes, offsetting a roughly …